|
|
|
|
Genedx Holdings Corp (NASDAQ: WGS) |
|
Price: $86.7200
$1.91 
2.252%
|
| Day's High:
| $87.27880096435547
| Week Perf:
| -2.82 %
|
| Day's Low: |
$ 83.70 |
30 Day Perf: |
22.31 % |
| Volume (M): |
500,130 |
52 Wk High: |
$ 170.87 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$93.55 |
| Open: |
$84.01 |
52 Wk Low: |
$32.21 |
|
|
| Market Capitalization (Millions $) |
2,544 |
| Shares
Outstanding (Millions) |
29 |
| Employees |
1,300 |
| Revenues (TTM) (Millions $) |
443 |
| Net Income (TTM) (Millions $) |
-78 |
| Cash Flow (TTM) (Millions $) |
-6 |
| Capital Exp. (TTM) (Millions $) |
19 |
Business Description
Genedx Holdings Corp is a biotechnology company that specializes in genetic testing and diagnostics. The company is focused on providing accurate and comprehensive genetic testing services to healthcare providers and patients. They offer a wide range of laboratory-developed tests for various genetic disorders, including rare and complex conditions. Genedx Holdings Corp aims to improve patient care by delivering precise and actionable genetic information. They also invest in research and development to continuously expand their test menu and advance the field of genetic testing.
Company Address: 333 Ludlow Street Stamford 6902 CT
Company Phone Number: 729-1206 Stock Exchange / Ticker: NASDAQ WGS
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Announcement
Published Fri, Aug 29 2025 7:50 PM UTC
GeneDx Holdings Corp. Under Investigation for Potential Misleading Business Information: Shareholders Rights at Stake NEW YORK, August 29, 2025 - In what could be a significant development for investors in the biotechnology sector, Rosen Law Firm, a globally recognized investor rights law firm, is actively investigating potential securities claims on behalf of shareholder...
|
| Announcement
Published Sun, Aug 3 2025 2:14 AM UTC
Understanding the Recent Developments at GeneDx Holdings Corp: A Closer Look at Potential Securities Claims and Financial PerformanceGeneDx Holdings Corp. (NASDAQ: WGS), a company known for its commitment to innovative solutions in genomic testing, has been thrust into the spotlight due to a recent press release from Rosen Law Firm. The release indicates ongoing investigati...
|
| Business Update
Published Thu, May 8 2025 4:17 AM UTC
GeneDx, a company recognized for its contributions to genomics and its capacity to promote better health outcomes, has announced a significant strategic move with the completion of its acquisition of Fabric Genomics. The integration of Fabric Genomics, heralded for its pioneering use of artificial intelligence in genomic interpretation, enhances GeneDx s portfolio in the lan...
|
| Business Update
Published Mon, Feb 24 2025 8:25 PM UTC
Revolutionary Genomic Testing: Transforming Neonatal Intensive Care and Newborn Screening Recent advancements in genomic testing have the potential to redefine neonatal intensive care unit (NICU) protocols and standards for newborn health screening. GeneDx, a trailblazer in genomic research and diagnostics, has made significant contributions to this rapidly evolving field. T...
|
| Business Update
Published Tue, Nov 19 2024 2:47 PM UTC
In a significant leap forward in the realm of personalized medicine, GeneDx, a leader in genomic health solutions, has launched GeneDx Discover, an innovative data visualization tool designed to enhance drug development for rare diseases. This pioneering initiative comes amid the company’s robust growth in the genetic testing sector and represents a transformational shift ...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-2.69 $ |
| Revenues (TTM) |
15.1 $
|
| Cash Flow (TTM) |
- |
| Cash |
5.82 $
|
| Book Value |
8.66 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
340,698 |
| Net
Income per Employee (TTM) |
-59,852 |
| Receivable Turnover Ratio (TTM) |
6.81 |
| Inventory Turnover Ratio (TTM) |
11.09 |
| Asset Turnover Ratio (TTM) |
0.89 |
|
|
| Per Share |
|
| Earnings (TTM) |
-2.69 $
|
| Revenues (TTM) |
15.1 $ |
| Cash Flow (TTM) |
- |
| Cash |
5.82 $
|
| Book Value |
8.66 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| GeneDx |
|
 99.3 % |
of total Revenue |
| Other |
|
0.74 % |
of total Revenue |
| Diagnostic test revenue |
|
99.11 % |
of total Revenue |
| Diagnostic test revenue GeneDx |
|
98.55 % |
of total Revenue |
| Diagnostic test revenue Other |
|
0.55 % |
of total Revenue |
| Patients with third-party insurance |
|
83.08 % |
of total Revenue |
| Patients with third-party insurance GeneDx |
|
83.08 % |
of total Revenue |
| Institutional customers |
|
15.75 % |
of total Revenue |
| Institutional customers GeneDx |
|
15.19 % |
of total Revenue |
| Institutional customers Other |
|
0.55 % |
of total Revenue |
| Self-pay patients |
|
0.28 % |
of total Revenue |
| Self-pay patients GeneDx |
|
0.28 % |
of total Revenue |
| Other GeneDx |
|
0.75 % |
of total Revenue |
| Other Other |
|
0.19 % |
of total Revenue |
| |
On February 20 2024 the Genedx Holdings provided following guidance
During the fourth quarter of 2023, GeneDx Holdings Corp. saw significant growth in revenue, with total revenue reaching a record high. The company's performance in 2023 was strong, with an increase in genetic testing volume and continued expansion of its test menu.
For the full year of 2023, GeneDx Holdings Corp. reported robust financial results, with revenue exceeding expectations. The company's continued focus on innovation and investment in technology has allowed it to maintain its position as a leader in genetic testing.
Looking ahead to 2024, GeneDx Holdings Corp. issued guidance for the full year, projecting continued growth and expansion. The company anticipates further increases in ge...
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
7.69%